Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.36 |
| ▸ | XIAP | P98170 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796815 | 0.88 | SRC (0.36) | SRCXIAPKDM4DAAK1NPY1R | |
| SCHEMBL26962100 | 0.88 | SRC (0.36) | SRCXIAPKDM4DAAK1NPY1R | |
| SCHEMBL26961755 | 0.88 | POLB (0.37) | SRCXIAPTRPA1KDM4DAAK1 | |
| SCHEMBL29796885 | 0.88 | SRC (0.38) | SRCXIAPTRPA1KDM4DAAK1 | |
| SCHEMBL26961886 | 0.88 | SRC (0.38) | SRCXIAPTRPA1KDM4DAAK1 | |
| SCHEMBL26961693 | 0.88 | SRC (0.39) | SRCXIAPKDM4DNPY1RSCN9A | |
| SCHEMBL29796974 | 0.88 | SRC (0.39) | SRCXIAPKDM4DNPY1RSCN9A | |
| SCHEMBL26962351 | 0.87 | XIAP (0.43) | SRCXIAPKDM4DNPY1RSCN9A | |
| SCHEMBL29796966 | 0.86 | SRC (0.39) | SRCXIAPKDM4DAAK1NPY1R | |
| SCHEMBL26961924 | 0.86 | SRC (0.39) | SRCXIAPKDM4DAAK1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4568958-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024033388-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | SCN1B, SCN2B, SCN11A | SRC 1591/4885XIAP 4823/4885TRPA1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.